adenosine (24 g/ml) alone in addition to nitrate when noreflow phenomenon occurred during PCI (between June 2001 and May 2002) and group II (25 patients, 66±9 years, 17 male) treated with combined intracoronary administration of adenosine and nicorandil (2 mg/ml) in addition to nitrate (between June 2002 and May 2003). In-hospital and 6-month major adverse cardiac events (MACE) after PCI were compared between the 2 groups.
Procedure
Diagnostic coronary angiography was performed via entry to the right (or left) femoral artery using the Seldinger method after local anesthesia of the inguinal area, or by insertion of a 6 French arterial sheath via the radial artery. Coronary angiograms of the left and right coronary arteries and the left ventricle were taken and stenosis of the internal diameter greater than 50% was regarded significant. On the coronary angiograms, the location of the culprit arteries, the Thrombolysis In Myocardial Infarction (TIMI) flow grade (TFG), 13 and type of lesions according to American College of Cardiology/American Heart Association (ACC/AHA) classfication 14 were analyzed and reference vessel internal diameters, minimal luminal diameters, and luminal stenoses of target arteries were measured using an on-line quantitative coronary angiogram program capable of edge detection (Philips H5000, The Netherlands). Elective or emergency PCI was performed according to its indications in patients who showed stenosis greater than 50% in more than 1 of 3 arteries on coronary angiography.
No-reflow phenomenon was defined as TFG 0 or I despite successful PCI such as balloon angioplasty or stent insertion. When no-reflow occurred, intracoronary injection of adenosine (24 g/ml) alone or in combination with nicorandil (2 mg/ml) was given to obtain TFG II or III. If no-reflow did not improve with one injection, another intracoronary injection was given 1 min later.
After drug administration, TFG, TIMI frame count (TFC) and myocardial blush score were checked and compared between the 2 groups.
Subjects who had undergone PCI had follow-up coronary angiography 6 months later or if there was recurrence of symptoms or they proved positive for restenosis on exercise stress testing or other non-invasive tests performed during the follow-up period. Restenosis was defined as stenosis greater than 50% on follow-up angiography in arteries with luminal stenosis less than 50% immediately after PCI.
Statistical Analysis
All data are described as mean ± standard deviation. Nominal variables were analyzed by chi-square test and various continuous variables were compared by t-test and chi-square and considered significant if the p-value was less than 0.05. Also, predictive factors were sought using multiple stepwise logistic regression analysis after adjustment for age, sex, and risk factors of coronary artery disease.
Results

Baseline Clinical Characteristics
Initial clinical diagnoses were 16 patients with ST segment elevation MI (STEMI) and 9 with non-ST segment elevation MI (NSTEMI) in group I, and 20 patients with STEMI and 9 with NSTEMI in group II (p=NS).
Mean age and sex were not significantly different between the groups. Left ventricular ejection fraction was 48.7±12.1% in group I versus 49.2±8.6 % in group II and left ventricular wall motion score was 29.5±4.5 in group I versus 28.9±4.7 in group II (p=NS). Risk factors of atherosclerosis such as smoking, diabetes, hypertension and hyperlipidemia were not significantly different between the 2 groups (Table 1) .
Coronary Angiographic and Procedural Characteristics
There were no significant differences in time interval from the onset of chest pain to PCI between the 2 groups. On coronary angiography, there were no significant differences in the number of culprit arteries, the distribution of arteries, types of lesions according to AHA/ACC classification or TFG before PCI between the 2 groups ( Table 2) . With regard to the procedural characteristics, there were 11 (44%) patients in group I and 10 (40%) in group II who developed thrombosis after balloon angioplasty, and 5 (20%) in group I and 4 (16%) in group II who developed coronary artery dissection. A platelet glycoprotein IIb/IIIa inhibitor was used in 9 (36%) patients in group I and 6 (24%) in group II. Stent deployment was performed in all 50 patients and there were no significant differences in stent size and length. After the no-reflow phenomenon occurred, mean number of injections of drugs given was 2.3±0.9 in group I and 1.8±0.7 in group II (p=0.019). Total adenosine dose was 55.0±20.6 g/ml in group I and 40.6± 16.8 g/ml in group II (p=0.008); total nicorandil dose was 0 mg/ml in group I and 3.5±1.3 mg/ml in group II (p< 0.001). TFG after PCI and ∆TFG were greater in group II than group I (TFG after PCI; 2.0±0.9 vs 2.6±0.6, p=0.024; ∆TFG; 1.5±1.1 vs 2.2±1.0, p=0.033) and the difference in TFC before and after PCI (∆TFC) was greater in group II than group I (63.6±23.2 vs 45.2±24.5, p=0.014, Table 3 ). Grade 3 myocardial blush score was obtained more frequently in group II than group I (76% vs 44%, p=0.014, Table 3 ). After PCI, cardiogenic shock because of noreflow occurred in 5 (20%) patients in group I and in 3 (12%) in group II, and the patients were treated with intraaortic balloon pump and inotrophic agents (Table 3) .
MACE During Hospitalization and Long-Term Clinical Follow up
Cardiac death occurred in 4 patients (16%) in group I (p=0.043): 2 of them (8%) had TFG 0 after PCI and the other 2 (8%) had TFG II after PCI. The cause of death was intractable ventricular arrhythmia. Another patient in group I (4%) with TFG 0 after PCI had a MI and target lesion revascularization during the in-hospital period (Table 4) . During the 6-month follow-up period, 2 patients (8%) from each group with TFG II after PCI underwent target lesion revascularization; heart failure occurred in 3 patients(12%) in group I (1 TFG 0, 1 TIMI I, 1 TIMI II after PCI) and in 1 patient (4%) in group II (TFG 0 after PCI). No MACE occurred in patients with TFG III after PCI (Table 4) .
Discussion
Successful reperfusion therapy of acute coronary syndrome is defined according to TFG: 0-I after reperfusion therapy is treatment failure whereas II-III is treatment success. 16 However, Ito et al reported that angiographically successful reflow cannot be used as an indicator of successful myocardial reperfusion in AMI patients. 17 In myocardial contrast echocardiography, the residual contrast defect in the risk area demonstrated immediately after reflow is a predictor of poor functional recovery of postischemic myocardium.
The mechanism of the no-reflow phenomenon is still unclear. Microvascular damage, and other mechanisms, after reperfusion therapy for AMI is thought to limit the completeness of tissue perfusion, despite the reopening of the epicardial vessel. 18 In the microvascular injury theory, effects on active vasomotility as well as interstitial edema formation because of ischemia or reperfusion are considered important in the development of no-reflow. 19 In another theory, distal embolism of a thrombus, including atheroemboli and plugging of the coronary microvasculature with plaque components, is responsible. In particular, activated platelets are known to release vasoactive substances and, therefore, the mechanism of no-reflow might be arterial contraction, in addition to capillary plugging. 20 Despite recanalization of the occluded artery, reperfusion at the level of the microcirculation may remain impaired because of microvascular reperfusion injury. Because of the combined effect of altered mitochondrial metabolism, xanthine oxydase, white blood cells and complement, more oxygen free-radicals are generated, which accelerates microvascular injury. 21 Endothelin and other vasconstrictors are secreted as a result and also play a role in the microvascular reaction and vasospasm. 22 Several methods are used to diagnose no-reflow, such as Doppler flow velocity, contrast enhanced echocardiography, contrast enhanced magnetic resonance image, and positron emission tomography. However, the most convenient and rapid method is the TFG: if it is 0-I after successful recanalization of the infarct-related artery, no-reflow is suspected. 23, 24 Another method, the TFC, is a simple, reproducible, objective and quantitative index of coronary flow that allows standardization of TFG. 25 There are several treatments for no-reflow, depending on the mechanism of this phenomenon. In the atheroembolic theory, platelets play the most important role, so the treatment includes antiplatelet drugs, such as a glycoprotein IIb/IIIa receptor blocker. In the case of vasoconstriction and microvascular injury, vasodilators such as adenosine also can be used. Adenosine affects intracellular calcium metabolism and inhibits neutrophil accumulation, superoxide generation and intracellular acidification by affecting glucose utilization. 27 In the AMISTAD trial, intravenous adenosine administration before thrombolytic therapy reduced the size of the MI by 33%; in particular, a 67% reduction in the size of anterior infarctions. 28 Other studies report that administration of adenosine as an adjunct to primary angioplasty reduces the incidence of no-reflow and improves ventricular function and clinical outcome. 29, 30 Nicorandil, an ATP-dependent potassium channel opener, protects cardiac myocytes by reducing the influx of calcium, inhibits neutrophil accumulation and activation, and reduces preload and afterload by its vasodilating effect. 31 Genda et al reported that ATP-sensitive potassium channel opening is related to the development of the noreflow phenomenon after PCI. 32 According to our results, intracoronary injection of combined adenosine and nicorandil is safe and provides a better result than adenosine alone on in-hospital death, TFG, TFC and the incidence of heart failure. No complication associated with the combined administration of adenosine and nicorandil was observed.
Study Limitations
This study was a non-randomized, retrospective analysis and the subjects were divided according to the availability of intravenous nicorandil. It was also a single center study of a small sample number. A large-scale, prospective, randomized study of a combined therapy group as well as adenosine and nicorandil alone groups should be performed.
